Francesca Polverino
Pulmonary Disease · Houston, TXNPI 1760140420
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $58,651 of the $75,266 with a category attached, or 77.9%. 10 manufacturers reported payments, led by Sanofi at 39.7% of the total. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 87 payments — averaging $865.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$30K
- AstraZeneca$19K
- Amgen$9K
- Astrazeneca UK Limited$8K
- Regeneron$4K
- Genentech, Inc.$4K
- plus $330 from 4 others
Across 1 payment — averaging $269,798 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$270K
What the payments were for
- Consulting fees$58,65178%
- Speaking & faculty fees$2,5983%
- Travel & lodging$11,01715%
- Food & beverage$3,0004%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 29 | $29,854 |
| AstraZeneca | 28 | $19,403 |
| Amgen | 10 | $9,228 |
| Astrazeneca UK Limited | 8 | $8,272 |
| Regeneron | 2 | $4,332 |
| Genentech, Inc. | 4 | $3,847 |
| Grifols Shared Services North America, Inc. | 1 | $120 |
| Regeneron Healthcare Solutions, Inc. | 3 | $95 |
| Polarean, Inc. | 1 | $88 |
| Verona Pharma, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$7,070
- FASENRA$4,431
- BREZTRI$2,986
- TEZSPIRE$135
- Prolastin-C Liquid$120
How this compares
$75,266 in reported general payments places this provider in the 90th percentile of 904 pulmonary disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 13 | $46,983 |
| Incruse ElliptaUmeclidinium Bromide | 33 | $4,366 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $1,185 |
| Fluticasone Propionate | 13 | $164 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Houston
- Nicola HananiaHouston$1.3M
- Sandeep SahayHouston$378K
- Zeenat SafdarHouston$291K
- Howard HuangHouston$194K
- Brandy McKelvyHouston$168K
- Alexander StadnykHouston$158K
- Lisa KopasHouston$120K
- Sandeep GuptaHouston$118K
- Roberto CasalHouston$113K
- Dileep PuppalaHouston$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.